RU2021119777A - Слитый полипептид, способный связывать cd137 и gpc3, молекула нуклеиновой кислоты, содержащая нуклеотидную последовательность, кодирующую такой слитый полипептид, способ его получения и пути применения - Google Patents
Слитый полипептид, способный связывать cd137 и gpc3, молекула нуклеиновой кислоты, содержащая нуклеотидную последовательность, кодирующую такой слитый полипептид, способ его получения и пути применения Download PDFInfo
- Publication number
- RU2021119777A RU2021119777A RU2021119777A RU2021119777A RU2021119777A RU 2021119777 A RU2021119777 A RU 2021119777A RU 2021119777 A RU2021119777 A RU 2021119777A RU 2021119777 A RU2021119777 A RU 2021119777A RU 2021119777 A RU2021119777 A RU 2021119777A
- Authority
- RU
- Russia
- Prior art keywords
- ser
- arg
- lys
- tyr
- leu
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title claims 88
- 108090000765 processed proteins & peptides Proteins 0.000 title claims 88
- 102000004196 processed proteins & peptides Human genes 0.000 title claims 88
- 102100032530 Glypican-3 Human genes 0.000 title claims 25
- 101001014668 Homo sapiens Glypican-3 Proteins 0.000 title claims 25
- 102000039446 nucleic acids Human genes 0.000 title claims 9
- 108020004707 nucleic acids Proteins 0.000 title claims 9
- 150000007523 nucleic acids Chemical class 0.000 title claims 9
- 239000002773 nucleotide Substances 0.000 title claims 2
- 230000004927 fusion Effects 0.000 claims 78
- 102000019298 Lipocalin Human genes 0.000 claims 20
- 108050006654 Lipocalin Proteins 0.000 claims 20
- 125000003275 alpha amino acid group Chemical group 0.000 claims 19
- 150000001413 amino acids Chemical class 0.000 claims 9
- 125000000539 amino acid group Chemical group 0.000 claims 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 6
- 210000001744 T-lymphocyte Anatomy 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 210000004881 tumor cell Anatomy 0.000 claims 5
- 239000012634 fragment Substances 0.000 claims 4
- 101000946124 Homo sapiens Lipocalin-1 Proteins 0.000 claims 3
- 230000004913 activation Effects 0.000 claims 3
- 230000001939 inductive effect Effects 0.000 claims 3
- 230000035772 mutation Effects 0.000 claims 3
- 238000006467 substitution reaction Methods 0.000 claims 3
- 108060003951 Immunoglobulin Proteins 0.000 claims 2
- 230000004988 N-glycosylation Effects 0.000 claims 2
- 230000007783 downstream signaling Effects 0.000 claims 2
- 102000018358 immunoglobulin Human genes 0.000 claims 2
- 230000004073 interleukin-2 production Effects 0.000 claims 2
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 claims 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 230000006044 T cell activation Effects 0.000 claims 1
- 230000005867 T cell response Effects 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 238000010353 genetic engineering Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15167927.1 | 2015-05-18 | ||
| EP15167927 | 2015-05-18 | ||
| EP16150508.6 | 2016-01-08 | ||
| EP16150508 | 2016-01-08 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017135539A Division RU2754466C2 (ru) | 2015-05-18 | 2016-05-18 | Слитый полипептид с противораковой активностью |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2021119777A true RU2021119777A (ru) | 2021-08-16 |
Family
ID=56134305
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2021119777A RU2021119777A (ru) | 2015-05-18 | 2016-05-18 | Слитый полипептид, способный связывать cd137 и gpc3, молекула нуклеиновой кислоты, содержащая нуклеотидную последовательность, кодирующую такой слитый полипептид, способ его получения и пути применения |
| RU2017135539A RU2754466C2 (ru) | 2015-05-18 | 2016-05-18 | Слитый полипептид с противораковой активностью |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017135539A RU2754466C2 (ru) | 2015-05-18 | 2016-05-18 | Слитый полипептид с противораковой активностью |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US10913778B2 (enExample) |
| EP (2) | EP4219535A1 (enExample) |
| JP (1) | JP6947642B2 (enExample) |
| KR (1) | KR102685748B1 (enExample) |
| CN (1) | CN108112253B (enExample) |
| AU (1) | AU2016262845B2 (enExample) |
| CA (1) | CA2980838A1 (enExample) |
| DK (1) | DK3298030T5 (enExample) |
| ES (1) | ES2938525T3 (enExample) |
| FI (1) | FI3298030T3 (enExample) |
| HR (1) | HRP20230145T1 (enExample) |
| HU (1) | HUE061108T2 (enExample) |
| LT (1) | LT3298030T (enExample) |
| MX (1) | MX390894B (enExample) |
| PL (1) | PL3298030T3 (enExample) |
| RS (1) | RS64002B1 (enExample) |
| RU (2) | RU2021119777A (enExample) |
| SG (1) | SG11201707426SA (enExample) |
| SI (1) | SI3298030T1 (enExample) |
| SM (1) | SMT202300026T1 (enExample) |
| WO (1) | WO2016184882A1 (enExample) |
| ZA (1) | ZA201706061B (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3094650A2 (en) * | 2014-01-13 | 2016-11-23 | Pieris Pharmaceuticals GmbH | Multi-specific polypeptide useful for localized tumor immunomodulation |
| DK3292137T3 (da) * | 2015-05-04 | 2022-10-17 | Pieris Pharmaceuticals Gmbh | Proteiner specifikke for cd137 |
| AU2016293101B2 (en) | 2015-07-15 | 2022-06-16 | Pieris Pharmaceuticals Gmbh | Novel proteins specific for LAG-3 |
| AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
| EP3565843A1 (en) * | 2017-01-03 | 2019-11-13 | H. Hoffnabb-La Roche Ag | Bispecific antigen binding molecules comprising anti-4-1bb clone 20h4.9 |
| US11814429B2 (en) | 2017-01-06 | 2023-11-14 | Crescendo Biologics Limited | Single domain antibodies to programmed cell death (PD-1) |
| JP7225116B2 (ja) * | 2017-01-18 | 2023-02-20 | ピエリス ファーマシューティカルズ ゲーエムベーハー | Ｌａｇ－３に対する結合親和性を有するリポカリンムテイン |
| WO2018134279A1 (en) * | 2017-01-18 | 2018-07-26 | Pieris Pharmaceuticals Gmbh | Novel fusion polypeptides specific for lag-3 and pd-1 |
| EP3710477A1 (en) * | 2017-11-13 | 2020-09-23 | Crescendo Biologics Limited | Single domain antibodies that bind to cd137 |
| GB201802573D0 (en) | 2018-02-16 | 2018-04-04 | Crescendo Biologics Ltd | Therapeutic molecules that bind to LAG3 |
| KR20200136949A (ko) | 2018-03-26 | 2020-12-08 | 4에스체 악티엔게젤샤프트 | 암 치료를 위한 hdac 억제제 및 cd137 작용제를 포함하는 배합물 |
| PL3830120T3 (pl) * | 2018-07-31 | 2023-10-09 | Pieris Pharmaceuticals Gmbh | NOWE BIAŁKO FUZYJNE SWOISTE WOBEC CD137 i PD-L1 |
| EP3931209A1 (en) * | 2019-02-26 | 2022-01-05 | Pieris Pharmaceuticals GmbH | Novel fusion proteins specific for cd137 and gpc3 |
| CA3127973A1 (en) * | 2019-03-29 | 2020-10-08 | Pieris Pharmaceuticals Gmbh | Inhaled administration of lipocalin muteins |
| WO2020208049A1 (en) * | 2019-04-12 | 2020-10-15 | F. Hoffmann-La Roche Ag | Bispecific antigen binding molecules comprising lipocalin muteins |
| PE20220500A1 (es) * | 2019-04-23 | 2022-04-07 | Lg Chemical Ltd | POLIPEPTIDO DE FUSION QUE COMPRENDE LA REGION Fc DE INMUNOGLOBULINA Y GDF15 |
| US20210009718A1 (en) | 2019-06-25 | 2021-01-14 | Gilead Sciences, Inc. | FLT3L-Fc FUSION PROTEINS AND METHODS OF USE |
| TWI862640B (zh) * | 2019-07-30 | 2024-11-21 | 英商拜西可泰克斯有限公司 | 異質雙環肽複合物 |
| CN115960242B (zh) * | 2021-09-09 | 2023-10-17 | 广东东阳光药业股份有限公司 | 抗癌结合分子及其应用 |
| IL319272A (en) * | 2022-09-21 | 2025-04-01 | Seagen Inc | ROVEL FUSION protein specific for CD137 and CD228 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE76311T1 (de) | 1986-08-19 | 1992-06-15 | Genentech Inc | Einrichtung und dispersion zum intrapulmonalen eingeben von polypeptidwuchsstoffen und zytokinen. |
| JPH01215289A (ja) | 1988-02-22 | 1989-08-29 | Toa Nenryo Kogyo Kk | 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法 |
| FR2649991B2 (fr) | 1988-08-05 | 1994-03-04 | Rhone Poulenc Sante | Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces |
| US5728553A (en) | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
| ATE299892T1 (de) | 1994-05-18 | 2005-08-15 | Nektar Therapeutics | Methoden und zusammensetzungen für die trockenpuderarznei aus interferonen |
| DE4417598A1 (de) | 1994-05-19 | 1995-12-14 | Max Planck Gesellschaft | Verwendung des Tetracyclinpromotors zur stringent regulierten Produktion von rekombinanten Proteinen in prokaryontischen Zellen |
| WO1996023879A1 (en) | 1995-01-30 | 1996-08-08 | Terrapin Technologies, Inc. | Glubodies - multiplicities of proteins capable of binding a variety of small molecules |
| US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| US6620413B1 (en) | 1995-12-27 | 2003-09-16 | Genentech, Inc. | OB protein-polymer chimeras |
| DE19641876B4 (de) | 1996-10-10 | 2011-09-29 | Iba Gmbh | Streptavidinmuteine |
| WO1998016873A1 (en) | 1996-10-14 | 1998-04-23 | Firm Forsat Ltd. | Method for preparing dispersions of chromogenic components |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| CA2233725A1 (en) | 1998-03-31 | 1999-09-30 | Hemosol Inc. | Hemoglobin-hydroxyethyl starch complexes |
| NZ508249A (en) | 1998-06-08 | 2003-02-28 | F | Use of PEG-IFN-alpha conjugates in association with ribavirin for the treatment of chronic hepatitis C |
| US6403564B1 (en) | 1998-10-16 | 2002-06-11 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
| DE19926068C1 (de) | 1999-06-08 | 2001-01-11 | Arne Skerra | Muteine des Bilin-Bindungsproteins |
| US7235520B2 (en) | 2000-09-21 | 2007-06-26 | University Of Massachusetts | Method of inducing apoptosis in lymphoid cells |
| CA2440582A1 (en) | 2001-03-09 | 2002-10-03 | Dyax Corp. | Serum albumin binding moieties |
| CA2464690A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of apolipoprotein d |
| WO2003029462A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
| AU2003275958A1 (en) | 2003-08-25 | 2005-03-10 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| US7691970B2 (en) | 2003-08-25 | 2010-04-06 | Pieris Ag | Muteins of a bilin-binding protein with affinity for a given target |
| US7288638B2 (en) * | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
| JP2007284351A (ja) | 2004-07-27 | 2007-11-01 | Osaka Bioscience Institute | アミロイド蛋白質の凝集を抑制する物質とその作用 |
| US7892827B2 (en) | 2004-11-26 | 2011-02-22 | Pieris Ag | Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4) |
| CA2622441A1 (en) | 2005-09-27 | 2007-04-05 | Amunix, Inc. | Proteinaceous pharmaceuticals and uses thereof |
| US20070087005A1 (en) | 2005-10-14 | 2007-04-19 | Lazar Gregory A | Anti-glypican-3 antibody |
| WO2007137170A2 (en) | 2006-05-20 | 2007-11-29 | Seattle Genetics, Inc. | Anti-glypican-3 antibody drug conjugates |
| US8313924B2 (en) | 2006-08-01 | 2012-11-20 | Pieris Ag | Muteins of tear lipocalin and methods for obtaining the same |
| ES2354653T3 (es) | 2006-08-01 | 2011-03-16 | Pieris Ag | Muteínas de lipocalina lacrimal y procedimientos para obtener las mismas. |
| ES2562790T3 (es) | 2007-07-17 | 2016-03-08 | E. R. Squibb & Sons, L.L.C. | Anticuerpos monoclonales contra Glipicano-3 |
| JP5746861B2 (ja) | 2007-10-19 | 2015-07-08 | アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ | 哺乳動物のｎｇａｌに結合する抗体及びその使用 |
| JP5711118B2 (ja) | 2008-06-24 | 2015-04-30 | テクニッシュ ウニヴェルジテート ミュンヘン | 所与の標的に対してアフィニティーを有するｈＮＧＡＬおよび類縁タンパク質のムテイン |
| RU2564125C2 (ru) | 2009-12-07 | 2015-09-27 | Пирис Аг | Мутеины липокалина 2 человека (lcn2, hngal) с аффинностью для определенной мишени |
| DK2606061T3 (da) | 2010-08-16 | 2017-11-06 | Pieris Pharmaceuticals Gmbh | Bindingsproteiner til hepcidin |
| CA2810359C (en) | 2010-09-09 | 2021-06-22 | Pfizer Inc. | 4-1bb binding molecules |
| AU2011331232B2 (en) | 2010-11-15 | 2015-05-07 | Pieris Ag | Muteins of human lipocalin 2 with affinity for Glypican-3 (GPC3) |
| WO2013174783A1 (en) * | 2012-05-23 | 2013-11-28 | Pieris Ag | Lipocalin muteins with binding-affinity for glypican-3 (gpc-3) and use of lipocalin muteins for target-specific delivery to cells expressing gpc-3 |
| CA2913029A1 (en) * | 2012-12-10 | 2014-06-19 | Fred Hutchinson Cancer Research Center | Lipocalin fusion partners |
| WO2014116846A2 (en) * | 2013-01-23 | 2014-07-31 | Abbvie, Inc. | Methods and compositions for modulating an immune response |
| CN104140974B (zh) * | 2013-05-08 | 2017-09-29 | 科济生物医药（上海）有限公司 | 编码gpc‑3嵌合抗原受体蛋白的核酸及表达gpc‑3嵌合抗原受体蛋白的t淋巴细胞 |
| EP3094650A2 (en) * | 2014-01-13 | 2016-11-23 | Pieris Pharmaceuticals GmbH | Multi-specific polypeptide useful for localized tumor immunomodulation |
| CA2943943C (en) * | 2014-04-07 | 2023-01-10 | Chugai Seiyaku Kabushiki Kaisha | Immunoactivating antigen-binding molecule |
| WO2016120307A1 (en) | 2015-01-28 | 2016-08-04 | Pieris Ag | Novel proteins specific for angiogenesis |
| WO2016131804A1 (en) | 2015-02-18 | 2016-08-25 | Sanofi | Novel proteins specific for pyoverdine and pyochelin |
| AU2016258977C1 (en) * | 2015-05-04 | 2022-07-14 | Pieris Pharmaceuticals Gmbh | Anti-cancer fusion polypeptide |
| DK3292137T3 (da) | 2015-05-04 | 2022-10-17 | Pieris Pharmaceuticals Gmbh | Proteiner specifikke for cd137 |
| BR112017020961A2 (pt) | 2015-05-18 | 2018-07-10 | Pieris Pharmaceuticals Gmbh | muteína, molécula de ácido nucleico, célula hospedeira, método de produção de uma muteína e método de ligação |
| TW201725212A (zh) | 2015-12-10 | 2017-07-16 | 第一三共股份有限公司 | 特異性於降鈣素基因相關胜肽的新穎蛋白 |
-
2016
- 2016-05-18 CA CA2980838A patent/CA2980838A1/en active Pending
- 2016-05-18 HR HRP20230145TT patent/HRP20230145T1/hr unknown
- 2016-05-18 FI FIEP16729794.4T patent/FI3298030T3/fi active
- 2016-05-18 ES ES16729794T patent/ES2938525T3/es active Active
- 2016-05-18 SM SM20230026T patent/SMT202300026T1/it unknown
- 2016-05-18 HU HUE16729794A patent/HUE061108T2/hu unknown
- 2016-05-18 KR KR1020177035641A patent/KR102685748B1/ko active Active
- 2016-05-18 RU RU2021119777A patent/RU2021119777A/ru unknown
- 2016-05-18 EP EP22216061.6A patent/EP4219535A1/en active Pending
- 2016-05-18 WO PCT/EP2016/061071 patent/WO2016184882A1/en not_active Ceased
- 2016-05-18 PL PL16729794.4T patent/PL3298030T3/pl unknown
- 2016-05-18 AU AU2016262845A patent/AU2016262845B2/en active Active
- 2016-05-18 SG SG11201707426SA patent/SG11201707426SA/en unknown
- 2016-05-18 US US15/575,309 patent/US10913778B2/en active Active
- 2016-05-18 RS RS20230084A patent/RS64002B1/sr unknown
- 2016-05-18 EP EP16729794.4A patent/EP3298030B1/en active Active
- 2016-05-18 MX MX2017014716A patent/MX390894B/es unknown
- 2016-05-18 CN CN201680028941.3A patent/CN108112253B/zh active Active
- 2016-05-18 DK DK16729794.4T patent/DK3298030T5/da active
- 2016-05-18 SI SI201631659T patent/SI3298030T1/sl unknown
- 2016-05-18 JP JP2017560331A patent/JP6947642B2/ja active Active
- 2016-05-18 LT LTEPPCT/EP2016/061071T patent/LT3298030T/lt unknown
- 2016-05-18 RU RU2017135539A patent/RU2754466C2/ru active
-
2017
- 2017-09-06 ZA ZA2017/06061A patent/ZA201706061B/en unknown
-
2021
- 2021-02-05 US US17/169,209 patent/US11919931B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2021119777A (ru) | Слитый полипептид, способный связывать cd137 и gpc3, молекула нуклеиновой кислоты, содержащая нуклеотидную последовательность, кодирующую такой слитый полипептид, способ его получения и пути применения | |
| RU2017135596A (ru) | Слитый полипептид с противораковой активностью | |
| RU2018107991A (ru) | Новый слитый полипептид, специфичный в отношении lag-3 и pd-1 | |
| JP2018519803A5 (enExample) | ||
| JP2018515085A5 (enExample) | ||
| RU2017135599A (ru) | Белки, специфичные в отношении cd137 | |
| US20240059751A1 (en) | Interleukin-2 variants and methods of uses thereof | |
| JP2018526989A5 (enExample) | ||
| AU2018390418B2 (en) | Engineered IL-2 Fc fusion proteins | |
| JP2017527272A5 (enExample) | ||
| FI3830120T3 (fi) | CD137:lle ja PD-L1:lle spesifinen uusi fuusioproteiini | |
| JP2018515084A5 (enExample) | ||
| ME02568B (me) | MUTIRANA Fc ANTITELA SA UKLONJENOM EFEKTORSKOM FUNKCIJOM | |
| JP2019522465A5 (enExample) | ||
| JP2007505643A5 (enExample) | ||
| HRP20220960T1 (hr) | Kimerni proteini faktora viii i njihova upotreba | |
| RU2017144098A (ru) | Гетеродимеризованный полипептид | |
| JP2015524799A5 (enExample) | ||
| IL308851B2 (en) | T-cell modulatory multimeric polypeptides and methods of use thereof | |
| JP2024153847A (ja) | 抗体のＦｃ領域改変体 | |
| JP2017512063A5 (enExample) | ||
| AU2020292421A1 (en) | Novel interleukin-2 variants and bifunctional fusion molecules thereof | |
| KR102247704B1 (ko) | 항 pd-1/항 her2 천연항체 구조 형태의 헤테로다이머 계의 이중특이성 항체 및 그 제조방법 | |
| CA3147044A1 (en) | Agents that interfere with thymic stromal lymphopoietin (tslp)-receptor signaling | |
| JPWO2020173897A5 (enExample) |